Top Doctor Top Doctor
The Top Doctor award is a peer-nominated award for providers who give exceptional care.

Edward N. Libby, MD

Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Oncology
“What gets me up in the morning is conducting research that improves your care.”
— Dr. Libby
What have you learned through working at SCCA?

Patients and their families are amazing; the suffering they endure without complaint so that they might once again resume their normal lives motivates me endlessly to improve treatment options. To them, I say thank you for sharing your lives with me and allowing me to be your physician. I’ve also learned how far we’ve come in the battle against formidable diseases like multiple myeloma — and just how far we have to go. We need more patients to participate in clinical trials, so that we can translate discoveries in the lab to successful therapies in the clinic.

How do you approach patient care?

Thomas Merton, an author and Trappist monk, once wrote, “Pride makes us artificial and humility makes us real.” We are on this journey together, and in order for me to be there for you in a genuine and beneficial way, humility is key. Just because I understand your disease doesn’t mean I grasp how it’s affecting you personally. Just because I know the clinically recommended treatment for your condition doesn’t mean it’s the right one for you. That’s why my motto is, “Listen, listen and then listen some more.” Humility leaves room for your voice so that we can make decisions together, manage uncertainties and remain open to changing the course of treatment, if needed.

Provider background

Specialty: Medical Oncology

Multiple myeloma and amyloidosis

I am a board-certified hematologist who specializes in treating patients with multiple myeloma, amyloidosis and other plasma cell (white blood cell) disorders. I provide daily care for patients who are newly diagnosed and those who have relapsed. I also have two decades of experience conducting clinical trials. One focus of my research is the use of monoclonal antibodies in the treatment of multiple myeloma. A targeted drug therapy, these antibodies attack myeloma cells while leaving healthy tissue intact. This class of drugs has proven effective for treating other conditions such as lymphoma, so we’re hopeful that these antibodies, when combined with other treatments, can also improve outcomes for patients with multiple myeloma.

Waldenstrom’s macroglobulinemia

Waldenstrom’s macroglobulinemia (WM) is a rare form of cancer that causes large amounts of an abnormal protein to build up in the blood. I enjoy collaborating with investigators across the country to treat patients with this disease. I am also active in researching drug therapies, such as rituximab, for the treatment of WM and other forms of lymphoma. In 2017, I was invited to present the latest clinical trial news on WM for an education forum hosted by the International Waldenstrom’s Macroglobulinemia Foundation.

Diseases treated

Education, experience and certifications
Undergraduate Degree
University of Texas
Medical Degree
University of Texas at Houston
University of New Mexico Health Sciences Center
University of New Mexico Comprehensive Cancer Center, Hematology
Board Certification
Hematology, 2006, 2017, American Board of Internal Medicine
Seattle Met's 2016 Top Doctors award

Dr. Libby received this peer-nominated award for his exceptional patient care.


“Dr. Libby is one of the most humble and hardworking people I know. He’s very dedicated to his patients — getting them on trials and delivering the latest therapies. He’s also very generous, always willing to share advice about how to manage patients with complex presentations. He’s a pillar of the myeloma community.”
— Daniel Martin, MD, Hematologist-Oncologist


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Complete title
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma
Study ID:
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
Complete title
Study ID:
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Complete title
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers